FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891566720> ?p ?o ?g. }

• W2891566720 abstract "7544 Background: In vitro studies of BTK and PI3K inhibitors demonstrate synergy in non-Hodgkin lymphoma (NHL). We embarked on a phase I/Ib investigator-initiated clinical trial evaluating the combination of ibrutinib (BTK inhibitor) and buparlisib (pan-PI3K inhibitor) in relapsed/refractory (R/R) NHL. The completed dose escalation is reported. Methods: Patients (pts) were eligible if they had R/R DLBCL, MCL, or FL with ECOG≤2 and adequate organ function. Ibrutinib and buparlisib were given daily by mouth on a 28-day cycle. Dose reductions were permitted after cycle 1. Tumor response was based on Lugano Classification however CR required both PET resolution and ≥ PR by CT. Results: As of Dec 16, 2016, 13 pts were enrolled and evaluated for toxicity (DLBCL 5, FL 2, MCL 6). Dose levels and DLT per table. Six pts discontinued treatment for disease progression (DLBCL 4, FL 2). Hematologic AE ≥ grade 3 are anemia (2), leukocytosis (2), and leukopenia (4). Relevant non-hematologic AEs of any grade ≥ 20% across all pts were fatigue (77%), diarrhea (62%), anorexia (54%), rash (46%), hyperbilirubinemia (46%), gastric reflux (46%), CMV reactivation (31%), mood change (31%), and hypertension (23%). Most common related grade 3/4 toxicity is rash (N = 3). No grade 5 toxicities noted. Serious adverse events (SAE) include: grade 2 pleural effusion and grade 2 nausea (N = 1), grade 1 fever with hospitalization (N = 1), grade 2 confusion and grade 4 hyponatremia (N = 1) were unrelated to therapy. Responses noted in 13 pts: MCL (N = 6: CR 4, PR 2), FL (N = 2: SD 2), DLBCL (N = 5: SD 1). One CR was a MCL pt with CR after 2 cycles on combination therapy and continues in remission on ibrutinib alone because of buparlisib toxicity. Conclusions: Combination of ibrutinib and buparlisib while generally well tolerated has predicted toxicities of both BTK and PI3K inhibitors. The recommended phase 2 dose is ibrutinib 560 mg and buparlisib 100 mg though dose reductions for tolerability may be needed for long term oral therapies. Promising efficacy is observed in MCL. Clinical trial information: NCT02756247. [Table: see text]" @default.
• W2891566720 created "2018-09-27" @default.
• W2891566720 creator A5000623885 @default.
• W2891566720 creator A5001102192 @default.
• W2891566720 creator A5003194253 @default.
• W2891566720 creator A5005950310 @default.
• W2891566720 creator A5006117950 @default.
• W2891566720 creator A5008468651 @default.
• W2891566720 creator A5012810450 @default.
• W2891566720 creator A5015672299 @default.
• W2891566720 creator A5024505450 @default.
• W2891566720 creator A5045676616 @default.
• W2891566720 creator A5049461398 @default.
• W2891566720 creator A5053498507 @default.
• W2891566720 creator A5053894847 @default.
• W2891566720 creator A5057941582 @default.
• W2891566720 creator A5061964017 @default.
• W2891566720 creator A5065054247 @default.
• W2891566720 creator A5068152076 @default.
• W2891566720 creator A5069406522 @default.
• W2891566720 creator A5069721801 @default.
• W2891566720 creator A5075482887 @default.
• W2891566720 date "2017-05-20" @default.
• W2891566720 modified "2023-10-12" @default.
• W2891566720 title "Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)." @default.
• W2891566720 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.7544" @default.
• W2891566720 hasPublicationYear "2017" @default.
• W2891566720 type Work @default.
• W2891566720 sameAs 2891566720 @default.
• W2891566720 citedByCount "3" @default.
• W2891566720 countsByYear W28915667202018 @default.
• W2891566720 countsByYear W28915667202020 @default.
• W2891566720 countsByYear W28915667202021 @default.
• W2891566720 crossrefType "journal-article" @default.
• W2891566720 hasAuthorship W2891566720A5000623885 @default.
• W2891566720 hasAuthorship W2891566720A5001102192 @default.
• W2891566720 hasAuthorship W2891566720A5003194253 @default.
• W2891566720 hasAuthorship W2891566720A5005950310 @default.
• W2891566720 hasAuthorship W2891566720A5006117950 @default.
• W2891566720 hasAuthorship W2891566720A5008468651 @default.
• W2891566720 hasAuthorship W2891566720A5012810450 @default.
• W2891566720 hasAuthorship W2891566720A5015672299 @default.
• W2891566720 hasAuthorship W2891566720A5024505450 @default.
• W2891566720 hasAuthorship W2891566720A5045676616 @default.
• W2891566720 hasAuthorship W2891566720A5049461398 @default.
• W2891566720 hasAuthorship W2891566720A5053498507 @default.
• W2891566720 hasAuthorship W2891566720A5053894847 @default.
• W2891566720 hasAuthorship W2891566720A5057941582 @default.
• W2891566720 hasAuthorship W2891566720A5061964017 @default.
• W2891566720 hasAuthorship W2891566720A5065054247 @default.
• W2891566720 hasAuthorship W2891566720A5068152076 @default.
• W2891566720 hasAuthorship W2891566720A5069406522 @default.
• W2891566720 hasAuthorship W2891566720A5069721801 @default.
• W2891566720 hasAuthorship W2891566720A5075482887 @default.
• W2891566720 hasConcept C121332964 @default.
• W2891566720 hasConcept C126322002 @default.
• W2891566720 hasConcept C142424586 @default.
• W2891566720 hasConcept C143998085 @default.
• W2891566720 hasConcept C2777058707 @default.
• W2891566720 hasConcept C2777525834 @default.
• W2891566720 hasConcept C2777938653 @default.
• W2891566720 hasConcept C2778461978 @default.
• W2891566720 hasConcept C2778559949 @default.
• W2891566720 hasConcept C2779338263 @default.
• W2891566720 hasConcept C2779878957 @default.
• W2891566720 hasConcept C502942594 @default.
• W2891566720 hasConcept C71924100 @default.
• W2891566720 hasConcept C87355193 @default.
• W2891566720 hasConceptScore W2891566720C121332964 @default.
• W2891566720 hasConceptScore W2891566720C126322002 @default.
• W2891566720 hasConceptScore W2891566720C142424586 @default.
• W2891566720 hasConceptScore W2891566720C143998085 @default.
• W2891566720 hasConceptScore W2891566720C2777058707 @default.
• W2891566720 hasConceptScore W2891566720C2777525834 @default.
• W2891566720 hasConceptScore W2891566720C2777938653 @default.
• W2891566720 hasConceptScore W2891566720C2778461978 @default.
• W2891566720 hasConceptScore W2891566720C2778559949 @default.
• W2891566720 hasConceptScore W2891566720C2779338263 @default.
• W2891566720 hasConceptScore W2891566720C2779878957 @default.
• W2891566720 hasConceptScore W2891566720C502942594 @default.
• W2891566720 hasConceptScore W2891566720C71924100 @default.
• W2891566720 hasConceptScore W2891566720C87355193 @default.
• W2891566720 hasLocation W28915667201 @default.
• W2891566720 hasOpenAccess W2891566720 @default.
• W2891566720 hasPrimaryLocation W28915667201 @default.
• W2891566720 hasRelatedWork W2163393078 @default.
• W2891566720 hasRelatedWork W2171285924 @default.
• W2891566720 hasRelatedWork W2475313937 @default.
• W2891566720 hasRelatedWork W2523635755 @default.
• W2891566720 hasRelatedWork W2604066363 @default.
• W2891566720 hasRelatedWork W2604305507 @default.
• W2891566720 hasRelatedWork W2621967241 @default.
• W2891566720 hasRelatedWork W2623638639 @default.
• W2891566720 hasRelatedWork W2731741866 @default.
• W2891566720 hasRelatedWork W2752938751 @default.
• W2891566720 hasRelatedWork W2791236038 @default.
• W2891566720 hasRelatedWork W2948124197 @default.
• W2891566720 hasRelatedWork W2951735615 @default.
• W2891566720 hasRelatedWork W2955736960 @default.
• W2891566720 hasRelatedWork W2959327776 @default.

• next